Massachusetts

Overview

Massachusetts legalized medical cannabis via Question 3 of the November 6, 2012 ballot (63% approval), codified at M.G.L. Chapter 94I. Adult-use cannabis was legalized via Question 4 of November 8, 2016 (53.7% approval) (the Regulation and Taxation of Marijuana Act) codified at M.G.L. Chapter 94G. Licensed adult-use retail sales began November 20, 2018, making Massachusetts the first East Coast state with operational adult-use retail.

Both programs are administered by the Massachusetts Cannabis Control Commission (CCC).

Adult-use (M.G.L. Chapter 94G, 2016)

• Public possession: 1 ounce of cannabis flower or 5 grams of concentrate.
• In-residence: up to 10 ounces at home.
• Home cultivation: up to 6 plants per adult, with a household cap of 12 plants. Plants must not be visible from a public place.
• Excise tax: 10.75% state cannabis excise tax + 6.25% state sales tax + up to 3% optional local sales tax.
• Gifting: transfers of up to one ounce between adults 21+ are permitted without compensation; sale without a license remains criminal.

Medical program (M.G.L. Chapter 94I, 2012)

Qualifying conditions

The medical program operates on a physician-certification standard. Enumerated conditions in regulation include:

• Cancer
• Glaucoma
• HIV/AIDS
• Hepatitis C
• ALS
• Crohn's disease
• Parkinson's disease
• Multiple sclerosis
• Other conditions as determined in writing by a qualifying patient's physician. Typically including severe and chronic pain, severe nausea, persistent muscle spasms, and seizures

Patient access

• Possession: 10 ounces of usable cannabis as a 60-day supply, with practitioner authority to exceed for clinical need.
• Approved forms: flower, edibles, oils, tinctures, capsules, vapes, topicals.
• Home cultivation: medical patients may apply for a hardship cultivation registration; otherwise, medical patients exercise the adult-use cultivation right of 6 plants per adult / 12 per household.
• Reciprocity: Massachusetts does not formally recognize out-of-state medical cards; visiting patients aged 21+ may purchase from any adult-use retailer.

Recreational penalties

Possession of cannabis in excess of adult-use limits is regulated under M.G.L. Chapter 94G §13 and Chapter 94C. Public consumption is prohibited and carries a civil fine. Open-container possession in a vehicle is a civil offense; operating under the influence remains criminal. Possession by individuals under 21 results in confiscation and may trigger a referral to drug-awareness programming.

Patients and caregivers

• Patient minimum age: 18. Minor patients require a designated caregiver and certification by two qualifying physicians.
• Caregiver minimum age: 21.
• Caregivers per patient: up to 2 personal caregivers per patient.
• Caregiver registration: via the Cannabis Control Commission; criminal background check.

Historical context

Massachusetts was the first New England state to legalize adult-use cannabis. The state's 2008 ballot initiative (Question 2) had earlier decriminalized possession of one ounce or less to a civil infraction, establishing the policy groundwork for the 2012 medical and 2016 adult-use measures. Massachusetts's social-equity provisions under Chapter 94G (including license preferences for applicants from areas disproportionately affected by prior cannabis enforcement) were among the earliest such measures in any state program.

Hemp and CBD legality

Massachusetts treats hemp under the Massachusetts Hemp Program administered by the Department of Agricultural Resources (MDAR) in alignment with the 2018 Federal Farm Bill (0.3% delta-9 THC by dry weight). CBD hemp products approved for sale must be registered with MDAR and meet labeling standards; products marketed as dietary supplements or that make therapeutic claims are restricted per MDAR Policy Statement on hemp-derived CBD.

MDAR and the Cannabis Control Commission (CCC) have taken the position that intoxicating hemp-derived cannabinoids — delta-8 THC, delta-10 THC, THC-O, HHC, and synthetic or chemically-converted cannabinoids — are not lawful for retail sale outside the licensed adult-use or medical-cannabis supply chain. The CCC's regulatory framework (935 CMR 500.000 for adult use, 935 CMR 501.000 for medical use) requires that any product containing detectable intoxicating cannabinoids be processed, tested, and sold through a CCC-licensed cannabis establishment.

Repeated legislative attempts to codify the prohibition by statute have advanced through committee without enactment, including H.124 / S.49 in the 2025-26 session and prior versions in 2023-24. Enforcement to date has been complaint-driven; MDAR has issued cease-and-desist orders to retailers selling intoxicating hemp products through general retail channels, and CCC inspections continue to focus on licensee compliance.

Smokable hemp flower is not specifically banned by Massachusetts statute and is offered at some retail outlets, but products with detectable intoxicating-cannabinoid content above MDAR thresholds remain subject to the cannabis-licensing framework. Industrial fiber and seed hemp under the MDAR Hemp Program operates separately and is unaffected by the cannabinoid-product rules.